Macrosalb (Macrosalb (99mtc))

Macrosalb contains macroaggregated albumin particles labeled with Technetium‑99m. After intravenous injection, the particles become temporarily lodged in the small vessels of the lung capillary network. The attached radioisotope emits gamma photons that are captured by a gamma camera, producing a visual map of regional lung perfusion.

The dose of Macrosalb is determined by the prescribing physician or nuclear medicine specialist based on the specific imaging protocol, patient weight, and equipment requirements. No fixed dosing regimen is provided here; the healthcare provider will calculate the appropriate activity at the time of the procedure.

Safety data for Macrosalb in pregnancy and lactation are limited. It should only be used when clearly needed, after a careful risk‑benefit assessment by the treating physician. If administered to a nursing mother, consideration should be given to discontinuing breastfeeding or evaluating potential exposure to the infant.

To order Macrosalb, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. The sales team will request trade or institutional credentials, then respond with pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

The primary alternative for lung perfusion imaging is Technetium‑99m‑labeled macroaggregated albumin from other manufacturers. Macrosalb offers comparable particle size distribution and radiochemical purity, meeting EU standards. Differences may lie in packaging, shelf‑life, or supplier support, but the clinical performance for perfusion imaging is generally equivalent.

Macrosalb kits should be stored at ambient temperature, preferably below 25 °C, in their original sealed packaging. Protect the product from direct light, moisture and extreme temperatures. After reconstitution, the solution should be used promptly according to the manufacturer’s instructions and handled with standard radiation safety precautions.

Macrosalb is supplied as a kit for reconstitution. The radiopharmaceutical is prepared by adding sterile diluent to the vial, mixing gently, and then injecting the resulting suspension intravenously. Administration is performed by qualified nuclear medicine personnel under aseptic conditions, typically immediately before the imaging study.

Serious risks include severe allergic reactions such as anaphylaxis, pulmonary hypertension, embolic phenomena where particles lodge outside the intended capillary bed, and radiation‑induced skin injury at the injection site. Immediate medical attention is required if any signs of anaphylaxis, sudden breathing difficulty, or unexplained chest pain occur.

Macrosalb should be avoided in patients with known hypersensitivity to albumin, technetium‑99m, or any component of the kit. It is also contraindicated in individuals with severe uncontrolled pulmonary hypertension or those who have recently received other radiopharmaceuticals or iodinated contrast agents that could interfere with imaging interpretation.